� Business Monitor International Ltd Page - Pharmaceutical SWOT Analysis - Continued Potential for further patented and branded product sector growth as healthcare system modernisation continues and the drug sector becomes more open. The growth of the private sector, which is characterised by high drug prices, assisting market growth in value terms. ...The growth of the private sector, which is characterised by high drug prices, assisting market growth in value terms. The decision to reduce the prices of drugs will benefit patients and contribute to the improvement of pharmaceutical services. The decision to reduce the prices of drugs will benefit patients and contribute to the improvement of pharmaceutical services. ...Greater cooperation with states outside the GCC could provide a further lift to domestic health services. Plans to modernize healthcare infrastructure could see it become a regional medical tourism destination, particularly for citizens of Iraq.
...Political instability to stall transition of the healthcare system from welfare state to a PPP system. Plans for regional harmonisation of prices, which would squeeze distribution margins. ...Restrictive reimbursement policy to remain in place for the near future. The government is actively tackling drug prices in the country, with measures such as a - cut for essential medicines and six-month price reviews. Competition from India and other countries exporting cheap medicines; counterfeit drugs are a growing concern. ...The government is actively tackling drug prices in the country, with measures such as a - cut for essential medicines and six-month price reviews. Competition from India and other countries exporting cheap medicines; counterfeit drugs are a growing concern.
...Reimbursement of high-priced medicines limited by government policies, forcing many patients to purchase the medicines on the private market or in neighbouring countries. Limited private-sector involvement in healthcare financing. ...